Endosense
Medical company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias.
Launch date
Employees
Market cap
-
Enterprise valuation
$170m (Public information from Mar 2017)
Company register number CHE-110.065.846
Geneva Canton of Geneva (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | £4.0m | Early VC | |
CHF26.0m | Series A | ||
$36.0m | Series B | ||
$40.3m | Series C | ||
| N/A | $4.3m | Series C | |
$170m Valuation: $170m | Acquisition | ||
| Total Funding | $110m | ||
Related Content
Recent News about Endosense
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.